Mainz Biomed EBITDA vs. Revenue
| MYNZ Stock | USD 0.22 0.04 15.38% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -25 M | Current Value -23.8 M | Quarterly Volatility 10 M |
For Mainz Biomed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mainz Biomed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mainz Biomed BV utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mainz Biomed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mainz Biomed BV over time as well as its relative position and ranking within its peers.
Mainz |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mainz Biomed. If investors know Mainz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mainz Biomed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.11) | Revenue Per Share 0.046 | Return On Assets (0.99) | Return On Equity (43.34) |
The market value of Mainz Biomed BV is measured differently than its book value, which is the value of Mainz that is recorded on the company's balance sheet. Investors also form their own opinion of Mainz Biomed's value that differs from its market value or its book value, called intrinsic value, which is Mainz Biomed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mainz Biomed's market value can be influenced by many factors that don't directly affect Mainz Biomed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mainz Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mainz Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mainz Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Mainz Biomed BV Revenue vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Mainz Biomed's current stock value. Our valuation model uses many indicators to compare Mainz Biomed value to that of its competitors to determine the firm's financial worth. Mainz Biomed BV is regarded fourth in ebitda category among its peers. It is regarded fifth in revenue category among its peers . Mainz Biomed reported EBITDA of (25.01 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mainz Biomed's earnings, one of the primary drivers of an investment's value.Mainz Revenue vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Mainz Biomed |
| = | (25.01 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Mainz Biomed |
| = | 895.48 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Mainz Revenue vs Competition
Mainz Biomed BV is regarded fifth in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 226.15 Million. Mainz Biomed adds roughly 895,479 in revenue claiming only tiny portion of equities under Health Care industry.
Mainz Biomed Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Mainz Biomed, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mainz Biomed will eventually generate negative long term returns. The profitability progress is the general direction of Mainz Biomed's change in net profit over the period of time. It can combine multiple indicators of Mainz Biomed, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 20.8 M | 11.7 M | |
| Net Interest Income | -809.6 K | -769.1 K | |
| Operating Income | -26.6 M | -25.3 M | |
| Net Loss | -26.3 M | -25 M | |
| Income Before Tax | -26.3 M | -25 M | |
| Total Other Income Expense Net | 349 K | 366.4 K | |
| Net Loss | -10.5 M | -10 M | |
| Net Loss | -26.3 M | -25 M | |
| Income Tax Expense | 1.9 M | 2 M | |
| Change To Netincome | 11.3 M | 11.9 M | |
| Net Loss | (1.62) | (1.70) | |
| Income Quality | 0.83 | 0.46 | |
| Net Income Per E B T | 1.15 | 1.31 |
Mainz Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Mainz Biomed. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mainz Biomed position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mainz Biomed's important profitability drivers and their relationship over time.
Use Mainz Biomed in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mainz Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mainz Biomed will appreciate offsetting losses from the drop in the long position's value.Mainz Biomed Pair Trading
Mainz Biomed BV Pair Trading Analysis
The ability to find closely correlated positions to Mainz Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mainz Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mainz Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mainz Biomed BV to buy it.
The correlation of Mainz Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mainz Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mainz Biomed BV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mainz Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Mainz Biomed position
In addition to having Mainz Biomed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Giant Impact Thematic Idea Now
Giant Impact
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.